MEDNAX (NYSE: MD ) reported earnings on July 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), MEDNAX beat expectations on revenues and earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew.
Margins dropped across the board.
MEDNAX booked revenue of $449.5 million. The 14 analysts polled by S&P Capital IQ looked for a top line of $437.1 million on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $393.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.22. The 15 earnings estimates compiled by S&P Capital IQ anticipated $1.19 per share. GAAP EPS of $1.22 for Q2 were 6.1% higher than the prior-year quarter's $1.15 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 34.6%, 150 basis points worse than the prior-year quarter. Operating margin was 22.2%, 150 basis points worse than the prior-year quarter. Net margin was 13.5%, 70 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $457.6 million. On the bottom line, the average EPS estimate is $1.26.
Next year's average estimate for revenue is $1.78 billion. The average EPS estimate is $4.71.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 181 members out of 186 rating the stock outperform, and five members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 53 give MEDNAX a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDNAX is outperform, with an average price target of $76.54.
If you're interested in health care stocks like MEDNAX, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Get instant access to this free report.
- Add MEDNAX to My Watchlist.